IONIS-HTTrx Proves Effectiveness in Treating Cause of HD
The study of IONIS-HTTRx was completed. The Phase 1/2a evaluated the first therapy in clinical development intended to target the underlying cause of Huntington’s Disease (HD).
George Yohrling of the HDSA Explains AMT-130 Gene Therapy
spoke with George Yohrling of the HDSA about AMT-130, uniQure N.V.’s gene therapy which received an Orphan Drug Designation in October.
George Yohrling of HDSA on Immunotherapy in Huntington's Disease
With altering the immune system in HD patients emerging as such a hot topic,
Rare Disease Report
sat down with George Yohrling to get his thoughts on whether this method is worth pursuing.
Spanish Study Reveals Role of ATF5 Protein in HD
A new study revealed that ATF5 proteins can become implanted in other substances in the brains of patients with Huntington’s disease.
Can Manipulating the Immune System Help Patients with Huntington's Disease?
Is the immune system involved in the progression of HD? And can drugs that target the immune system help HD patients?
Can a Blood Pressure Medication Help HD Patients?
Can rilmenidine delay disease progression in Huntington's disease? Cambridge researchers are trying to find out.
Celebrating 50 Years of the Huntington's Disease Society of America
Louise Vetter discusses 50 years of the HDSA, and insight as to why she continues to fight on behalf of families affected by Huntington's disease.
Gene Therapy for HD Continues to Show Promise
The administration of AMT-130 into the mouse striatum led to significant improvements in motor symptoms and survival.
Louise Vetter Previews "Her Mother's Daughter" and Stresses Storytelling in Rare
Louise Vetter stresses the importance of storytelling in rare diseases, and why film is such a powerful tool to convey messages that need to be heard.
Marjorie Guthrie's Impact on Rare Disease Advocacy
In this video, Louise Vetter, President and CEO of the HDSA talks about Marjorie Guthrie’s impact on the rare disease community and the creation of NORD.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.